Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Intact transferrin and total plasma glycoprofiling for diagnosis and therapy monitoring in phosphoglucomutase-I deficiency

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Troubleshooting in advanced VATS procedures

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Erratum to semaglutide seems to be more effective the other GLP-1Ras

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The subtypes of microscopic colitis from a pathologist's perspective: past, present and future

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Phenotypic Spectrum of α-Dystroglycanopathies Associated With the c.919T>a Variant in the FKRP Gene in Humans and Mice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vacuoles, Often Containing Glycogen, Are a Consistent Finding in Hypokalemic Periodic Paralysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Nurulamin Abu Bakar
  • Nicol C Voermans
  • Thorsten Marquardt
  • Christian Thiel
  • Mirian C H Janssen
  • Hana Hansikova
  • Ellen Crushell
  • Jolanta Sykut-Cegielska
  • Francis Bowling
  • Lars MØrkrid
  • John Vissing
  • Eva Morava
  • Monique van Scherpenzeel
  • Dirk J Lefeber
Vis graf over relationer

Phosphoglucomutase 1 (PGM1) deficiency results in a mixed phenotype of a Glycogen Storage Disorder and a Congenital Disorder of Glycosylation (CDG). Screening for abnormal glycosylation has identified more than 40 patients, manifesting with a broad clinical and biochemical spectrum which complicates diagnosis. Together with the availability of D-galactose as dietary therapy, there is an urgent need for specific glycomarkers for early diagnosis and treatment monitoring. We performed glycomics profiling by high-resolution QTOF mass spectrometry in a series of 19 PGM1-CDG patients, covering a broad range of biochemical and clinical severity. Bioinformatics and statistical analysis were used to select glycomarkers for diagnostics and define glycan-indexes for treatment monitoring. Using 3 transferrin glycobiomarkers, all PGM1-CDG patients were diagnosed with 100% specificity and sensitivity. Total plasma glycoprofiling showed an increase in high mannose glycans and fucosylation, while global galactosylation and sialylation were severely decreased. For treatment monitoring, we defined 3 glycan-indexes, reflecting normal glycosylation, a lack of complete glycans (LOCGI) and of galactose residues (LOGI). These indexes showed improved glycosylation upon D-galactose treatment with a fast and near-normalization of the galactose index (LOGI) in 6 out of 8 patients and a slower normalization of the LOCGI in all patients. Total plasma glycoprofiling showed improvement of the global high mannose glycans, fucosylation, sialylation, and galactosylation status on D-galactose treatment. Our study indicates specific glycomarkers for diagnosis of mildly and severely affected PGM1-CDG patients, and to monitor the glycan-specific effects of D-galactose therapy.

OriginalsprogEngelsk
TidsskriftAnnals of Translational Medicine
Vol/bind199
Sider (fra-til)62-76
Antal sider15
ISSN1479-5876
DOI
StatusUdgivet - sep. 2018

ID: 55680185